Prolacta Bioscience

prolacta.com

Prolacta Bioscience is the pioneer in human milk-based nutritional products for premature infants in the neonatal intensive care unit (NICU). Prolacta believes that there is no adequate replacement for human breast milk and, as such, we believe infant nutritional products should be human milk-based. As a privately held, scientifically driven company, committed to improving premature infant nutrition, we are using human milk to change the standard of care in the NICU. Mothers who have a surplus of breast milk can help save the country's most fragile infants by donating their extra breast milk to one of Prolacta's affiliate milk banks.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

news image

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More

MedTech

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

news image

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More

MedTech

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

news image

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More

Research

INSTITUTE FOR BIOSCIENCE AND BIOTECHNOLOGY RESEARCH RECEIVES $16.8 M INVESTMENT FROM THE NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY

Institute for Bioscience and Biotechnology Research | January 14, 2022

news image

The Institute for Bioscience and Biotechnology Research announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments...

Read More
news image

Cell and Gene Therapy

MEKONOS RAISES $4.6M FINANCING ROUND FOR TARGETED EX VIVO GENE ENGINEERING

Mekonos | November 24, 2020

Mekonos, a biotech organization launching the first-of-its kind system-on-a-chip (SoC) for focused ex vivo gene engineering, today reported it has finished a $4.6 million financing round. Mekonos will utilize the new funding to quicken the SoC stage for its current and new ad organizations. The SoC stage, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The stage is versatile over all cell types and has demonstrated to ...

Read More
news image

MedTech

NOVOZYMES AND SAIPEM ENTER COLLABORATION AGREEMENT TO CREATE A MORE SUSTAINABLE CO2 CAPTURE

Novozymes | December 13, 2021

Novozymes, the world leader in biological solutions, and Saipem, an advanced technological and engineering platform for safe and sustainable complex infrastructure and plants, have signed a collaboration agreement for the development of innovative solutions for enzymatic carbon capture. As part of the agreement, Saipem - which owns an enzyme-based CO2 capture technology - will be responsible for providing process, mechanical and equipment design, while Novozymes will provide enzym...

Read More
news image

MedTech

VERSANTIS TO PRESENT POSITIVE PHASE 1B DATA AT AASLD FOR VS-01 IN PATIENTS WITH DECOMPENSATED CIRRHOSIS

Versantis | November 15, 2021

Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, announced that positive Phase 1b clinical data from a study of its lead investigational, orphan-designated product, VS-01, in 12 hospitalized patients with decompensated liver cirrhosis will be presented at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data show that VS-01 was safe and well tolerated in these patients, and demonstrated promi...

Read More
news image

Research

INSTITUTE FOR BIOSCIENCE AND BIOTECHNOLOGY RESEARCH RECEIVES $16.8 M INVESTMENT FROM THE NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY

Institute for Bioscience and Biotechnology Research | January 14, 2022

The Institute for Bioscience and Biotechnology Research announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us